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 Abstract  
Hepatitis B virus (HBV) is designated a “metabolovirus” due to the intimate connection 
between the virus and host metabolism. The nutrition state of the host plays a relevant role in 
the severity of HBV infection. Metabolic syndrome (MS) is prone to increasing HBV DNA 
loads and accelerating the progression of liver disease in patients with chronic hepatitis B 
(CHB). Cluster of differentiation 36 (CD36), also named fatty acid translocase, is known to 
facilitate long-chain fatty acid uptake and contribute to the development of MS. We recently 
found that CD36 overexpression enhanced HBV replication. In this study, we further explored 
the mechanism by which CD36 overexpression promotes HBV replication. Our data showed 
that CD36 overexpression increased HBV replication, and CD36 knockdown inhibited HBV 
replication. RNA sequencing found some of the differentially expressed genes were involved 
in calcium ion homeostasis. CD36 overexpression elevated the cytosolic calcium level, and 
CD36 knockdown decreased the cytosolic calcium level. Calcium chelator BAPTA-AM could 
override the HBV replication increased by CD36 overexpression, and the calcium activator 
thapsigargin could improve the HBV replication reduced by CD36 knockdown. We further 
found that CD36 overexpression activated Src kinase, which plays an important role in the 
regulation of the store-operated Ca2+ channel. An inhibitor of Src kinase (SU6656) significantly 
reduced the CD36-induced HBV replication. We identified a novel link between CD36 and 
HBV replication, which is associated with cytosolic calcium and the Src kinase pathway. CD36 
may represent a potential therapeutic target for the treatment of CHB patients with MS.  





Hepatitis B virus (HBV) is a small DNA virus that predominately infects liver cells and is 
the most common cause of hepatitis, cirrhosis and hepatocellular carcinoma [1]. It is also 
designated a “metabolovirus” due to the intimate connection between the virus and host 
metabolism [2]. HBV transcription and replication is regulated mainly by the recruitment of a 
variety of cellular transcription factors to its promoters and enhancers, some of which are linked 
to host metabolic processes [3]. Several epidemiological studies demonstrated that the 
individual diet and host nutrition state play relevant roles in the severity of HBV infection [4]. 
Starvation and fasting increased HBV transcription and gene expression [5]. Bile acids also 
increased HBV transcription and gene expression in vitro experiments [6]. Host cholesterol was 
an essential element for HBV assembly and viral infection [7,8]. These results suggested that 
the host metabolic changes generate a permissive milieu that may be advantageous to the HBV 
life cycle.  
The number of chronic hepatitis B (CHB) patients with concomitant metabolic diseases 
has increased gradually. A recent study reported that 13% of CHB patients had metabolic 
syndrome (MS), and the prevalence of liver cirrhosis was higher in CHB patients with MS (38%) 
than those without MS (11%) [9]. A population-based study showed that CHB patients with MS 
had significantly higher levels of HBV DNA loads compared to those without MS [10]. High 
viral load is considered an important risk factor for the development of liver cirrhosis and 
hepatocellular carcinoma in CHB patients. Therefore, further exploration of the hepatic 
metabolic factors that control HBV replication may be an important step in the treatment 
strategies for CHB patients with MS. 
Cluster of differentiation 36 (CD36), also named fatty acid translocase, belongs to the 
scavenger receptor family and is a transmembrane glycoprotein found on the surface of many 
cell types in vertebrates [11]. It is a facilitator of long-chain fatty acid transport and other 
biologically active lipids, such as ox-LDL. With many ligands and functions, CD36 could have 
an influence on various conditions associated with MS, atherosclerosis and non-alcoholic fatty 
liver disease (NAFLD) [12]. The expression of CD36 was weak in the normal liver, but a mouse 
model showed that its expression was significantly increased during high fatty acid feeding [13]. 
Clinical studies also exhibited higher soluble CD36 in patients with NAFLD and MS [14,15]. 
Recent studies demonstrated that a chronic HBV immune tolerant phase characterized by high 
levels of HBV replication had higher levels of free fatty acids compared with healthy controls 
[16]. In addition, elevated levels of total fatty acids are clearly induced in the HBV-replicating 
cell line HepG2.2.15 [17]. However, whether CD36 is a molecular bridge between fatty acid 
metabolism and HBV replication is largely unknown.  
Our previous study found that the expression of CD36 was increased in the HBV-
replicating cell line, and CD36 overexpression enhanced HBV replication, but the mechanism 
is still unknown [18]. In this study, we aimed to investigate the molecular mechanism by which 
CD36 overexpression enhanced HBV replication.  
2. Materials and methods 
2.1 Cell culture and construction 
HepG2.2.15 and HepAD38 cells were cultured in modified Eagle’s medium (MEM) 
containing 10% fetal calf serum and 500µg/mL G418. To stably overexpress CD36 in 
HepG2.2.15 and HepAD38 cells, a human CD36 overexpression lentivirus system was 
constructed, packaged, and purified by GeneChem (Shanghai, China). CD36-overexpression-
lentivirus and vector-lentivirus were transfected into HepG2.2.15 and HepAD38 cells according 
to the manufacturer’s protocol. To generate CD36 knockdown cells, a lentivirus system 
expressing CD36 shRNA was constructed by GeneChem. The CD36 shRNA targeting sequence 
was as follows: 5’-GGCTGTGTTTGGAGGTATTCT-3’. CD36-shRNA-lentivirus and 
scramble control-lentivirus were transfected into HepG2.2.15 and HepAD38 cells according to 
the manufacturer’s protocol. 
2.2 Purification and quantification of core particles associated with HBV DNA from HBV-
replicating cells  
Core particles associated with HBV DNA were extracted from equal numbers of cells 96 
h after transfection. Cells were collected, and cell number was counted using an Innovatis 
Cedex XS Analyzer (Roche, Bielefeld, Germany). Next, cells were washed with PBS and lysed 
with 500 µL of lysis buffer (50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1% NP-40) at room 
temperature for 30 min. Cell nuclei were pelleted by centrifugation for 1 minute at 10 000 g. 
Then, the supernatant was treated with 60 U of DNase I and 10 mM MgCl2 for 4 h at 37°C and 
centrifuged again. The supernatant was supplemented with 200 µL of 35% PEG8000 containing 
1.5 M NaCl and rested on ice for 40 minutes. Then, the pellet of the virus core particles was 
collected after centrifugation at 12 000 g for 5 min at 4°C. The virus core particles were digested 
overnight at 42°C in 500 µL digestion buffer (0.5 mg /mL proteinase K, 25 mM Tris-HCl (pH 
8.0), 0.5% SDS, 150 mM NaCl, and 10 mM EDTA). HBV DNA in the digestion mixture was 
extracted twice with phenol-chloroform (1:1), precipitated with ethanol and glycogen, and 
dissolved in ddH2O. HBV DNA was analyzed by southern blot (DIG-High Prime DNA 
Labeling and Detection Starter Kit II, Roche, Rotkreuz, Switzerland) and real-time PCR using 
the SYBR Green method (Takara, Dalian, China). The forward and reverse primers were as 
follows:  5′- TGCGGCGTTTTATCATATTCC -3′ and 5′- 
ATACCTTGGTAGTCCAGAAGAACCA-3′, respectively. 
To determine the effect of chemical reagents on the process of CD36 affecting HBV 
replication, CD36 overexpression cells were treated with calcium chelator BAPTA-AM 
(Selleck, Houston, TX, USA) at a concentration of 25 μM and Src family kinase inhibitor 
SU6656 (Selleck, Houston, TX, USA) at a concentration of 0.6 μM, and CD36 knockdown 
cells were treated with calcium mobilizing agent thapsigargin (Sigma-Aldrich, St. Louis, MO, 
USA) at a concentration of 5 nM and 2.5 nM in HepAD38 and HepG2.2.15, respectively. After 
96 h, the HBV DNA was extracted and measured by real-time PCR, as described above. Cell 
viability under each condition was assayed by using trypan blue. 
2.3 Measurement of the secreted HBsAg and HBeAg 
The concentrations of HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) in the 
culture medium were detected by the enzyme-linked immunosorbent assay (ELISA) kit (KHB, 
Shanghai, China) according to the manufacturer’s protocols.  
2.4 Animal study 
To build the mouse model of acute hepatitis B virus infection, 9-week-old male C57BL/6 
wild type (WT) and CD36 knockout (CD36KO) mice were used. CD36KO mice created on a 
C57BL/6 background were kindly provided by Dr. Maria Febbraio (Lerner Research Institute, 
U.S.). All animal studies were conducted according to the protocol approved by the Institutional 
Animal Care and Use Committee at Chongqing Medical University. A total of 20 μg of pGEM-
HBV1.3 plasmid was injected into the tail veins of mice in a volume of saline equivalent to 8% 
of the mouse body weight within 5-8 s. The serum and liver tissue samples were collected on 
the fifth day. The levels of HBsAg and HBeAg were measured by chemiluminescence 
immunoassay (Abbott Architect, USA). HBV DNA in the serum and liver was extracted using 
the Hipure viral DNA mini kit (Magen, Guangzou, China) and measured by real-time PCR, as 
described above. The HBV core protein of liver tissue was visualized by immunohistochemical 
staining using anti-HBc antigen antibody (1:100, Abcam, Cambridge, UK).  
2.5 Cytosolic calcium analysis 
Cells were cultured in a 6-well plate. At 48 h posttransfection, cells were washed with D-
Hanks buffer (without Ca2+ and Mg2+) two times and then incubated with 4 μM fluorescent Ca2+ 
indicator Fluo-4/AM (life technologies, Grand Island, NY, USA) and 2.5 mM probenecid (Life 
Technologies, Grand Island, NY, USA) at 37°C and 5% CO2 in the dark for 30 minutes and then 
at room temperature for an additional 30 minutes. Cells were digested with trypsin and 
precipitated by centrifugation. Cell pellets were washed in cold D-Hanks buffer twice and 
resuspended in 500 μL D-Hanks buffer. The concentration of intracellular calcium was 
measured using FACSCanto™ II flow cytometry (BD, FranklinLakes, NJ, USA) by excitation 
with a 488 nm argon laser line and was shown by mean fluorescence. Data were collected from 
more than 10,000 cells for each sample. The Ca2+ concentrations were expressed as relative 
fluorescence. 
To determine the role of calcium reagents in reducing and elevating cytosolic calcium, 
CD36 overexpression cells were treated with calcium chelator BAPTA-AM at a concentration 
of 25 μM, and CD36 knockdown cells were treated with calcium mobilizing agent thapsigargin 
at concentrations of 5 nM and 2.5 nM in HepAD38 and HepG2.2.15, respectively. After 48 h, 
the concentration of intracellular calcium was measured, as described above. Cell viability 
under each condition was assayed using trypan blue. 
2.6 Western blotting  
Cells were lysed using RIPA containing a protease inhibitor cocktail and phosphatase 
inhibitor cocktail, and the protein content was measured and normalized using a BCA protein 
assay kit. Total proteins (50 µg) were separated by SDS-PAGE and transferred onto PVDF 
membranes. After blocking with 3% BSA, the membranes were incubated with primary 
antibodies: anti-CD36, 1:2000 (Abcam, Cambridge, UK); anti-Src, anti-p-Src, 1:2000 (CST, 
Danvers, MA, USA); anti-actin, 1:4000, (ProteinTech, Wuhan, China), at 4°C overnight and 
subsequently incubated with the corresponding horseradish peroxidase (HRP)-conjugated 
secondary antibodies. Finally, the blot was detected using an ECL advance western blotting 
detection kit (Millipore, Temecula, CA, USA). The protein signal intensity was analyzed using 
ImageJ software (National Institutes of Health, USA).  
2.7 Measurement of the production of Inositol 1,4,5-Triphosphate (IP3) by ELISA 
Cells were cultured in a 10-cm plate. IP3 was extracted from equal numbers of cells at 72 
h. IP3 levels in the cytoplasm were measured with a human IP3 ELISA kit (SinoBestBio, 
Shanghai, China). 
2.8 Statistics  
Experimental data are shown as the means  standard deviations. The t-test was applied to 
comparisons between different groups; values of P < 0.05 were considered to indicate statistical 
significance. Statistical analysis was performed using GraghPad Prism software. 
3. Results 
3.1 CD36 overexpression promoted HBV replication in vitro 
HepG2.2.15 and HepAD38 cells, which support stable HBV replication, protein 
expression, and virion assembly and secretion, were infected with recombinant lentivirus 
expressing CD36 cDNA to obtain stable CD36 overexpression (CD36OE) cell line models. 
There were significant increases in CD36 protein levels in the CD36OE group compared with 
in the vector group (Figure 1A), suggesting that CD36 overexpression was successfully 
established in both cell lines. HBV DNA replicative intermediates were detected by both real-
time PCR and southern blot. The data showed that CD36 overexpression induced significantly 
elevated levels of HBV DNA in both cell lines (Figure 1B and 1C). Meanwhile, CD36 
overexpression significantly elevated the levels of HBsAg and HBeAg compared with those in 
the vector group (Figure 1C). These data suggested that CD36 overexpression could enhance 
HBV replication. 
3.2 CD36 knockdown inhibited HBV replication in vitro and in vivo 
As shown in Figure 2A, CD36 expression was efficiently downregulated in shRNA-
targeting CD36 (shCD36) compared with shRNA-scramble control (shCont) in both 
HepG2.2.15 and HepAD38 cells, suggesting that stable CD36 knockdown cell lines were 
successfully established. CD36 knockdown resulted in decreased levels of HBV DNA 
replicative intermediates in both cells (Figure 2B and 2C). Gene silencing of CD36 significantly 
inhibited HBsAg and HBeAg secretions (Figure 2C). These data suggested that CD36 
knockdown inhibited HBV replication.  
In an acute HBV infection mouse model, the serum HBsAg and HBeAg levels were 
significantly decreased in CD36 knockout (CD36 KO) mice compared with in wild type (WT) 
mice (Figure 2D). Moreover, the levels of HBV DNA in the serum and liver were remarkably 
decreased in CD36 KO mice compared with in WT mice (Figure 2D). The expression of HBcAg 
in livers from the two groups of mice was detected by immunohistochemical staining. The 
frequency of HBcAg-positive hepatocytes decreased significantly in CD36 KO mice compared 
with in WT mice (Figure 2D). These data in vivo were similar to those in vitro. 
3.3 CD36 expression affected the levels of cytosolic calcium in vitro 
To explore the molecular mechanism by which CD36 affects HBV replication, we 
performed RNA sequencing of the mRNA from HepG2.2.15-CD36OE cells and HepG2.2.15-
vector cells to understand the differential transcriptomic profile. Our results showed that some 
of the differentially expressed genes, such as KCNK10, SCN9A, and S100A3, were involved 
in the potassium voltage-gated channel, sodium voltage-gated channel and calcium binding 
protein (Figure 3A). Next, we specially focus on the potential role of CD36 in calcium ion 
homeostasis, which supports HBV replication and assembly, as shown in previous studies 
[19,20]. We found that CD36 overexpression significantly increased the levels of cytosolic 
calcium and CD36 knockdown decreased the levels of cytosolic calcium, as evidenced by flow 
cytometry (Figure 3B and 3C), suggesting that CD36 expression affected the levels of cytosolic 
calcium in both HepG2.2.15 and HepAD38 cells. 
3.4 Cytosolic calcium signals involved in CD36-mediated regulation of HBV replication in vitro  
Furthermore, the data showed that the calcium chelator BAPTA-AM reduces cytosolic 
calcium in CD36 overexpression cells (Figure 4A), while the calcium mobilizing agent 
thapsigargin increases cytosolic calcium in shCD36 cells (Figure 4B). The levels of HBV DNA 
were decreased in the BAPTA-AM-treated CD36OE group compared with in the untreated 
group, and the levels of HBV DNA were increased in thapsigargin treated shCD36 cells (Figure 
4A and 4B), suggesting that CD36 was implicated in HBV replication by cytosolic calcium. 
3.5 CD36 overexpression enhanced HBV replication by activating Src kinase 
CD36 has been linked to the phosphorylation of Src kinases, which play an important role 
in the regulation of calcium influx [21,22]. The activity of Src kinases is regulated by the 
phosphorylation at the Tyr416 site in the activation loop domain to upregulate enzyme activity 
[23]. We investigated the effect of CD36 overexpression on the activity of Src kinase in 
HepG2.2.15 and HepAD38 cells. The data demonstrated that CD36 overexpression enhances 
the Tyr416 phosphorylation of Src kinase in both cells (Figure 5A). Previous studies suggested 
that the activation of Src kinase could enhance calcium released from the endoplasmic reticulum 
pool to increase the free intracellular calcium concentrations by an inositol 1,4,5-
triphosphate(IP3)-dependent mechanism [24]. Here, CD36 overexpression elevates the levels 
of cytoplasm IP3 compared with vector control cells (Figure 5B). We further investigated the 
role of Src kinase in the CD36-induced HBV replication using a selective inhibitor of Src kinase 
SU6656. Our data showed that the Src kinase inhibitor SU6656 significantly diminished the 
CD36-induced increases of IP3, cytosolic calcium and HBV replication in both CD36 
overexpression cells (Figure 5B, 5C and 5D). These results suggest that CD36 overexpression 
facilitated the phosphorylation of Src kinase to regulate HBV replication.  
4. Discussion 
  HBV is an enveloped DNA virus that requires host lipid for the viral envelope and 
surface antigen particles [25,26]. The dysregulated lipid profile and altered lipid-related genes 
are likely due to metabolic hijacking by HBV in favor of its viral replication. A study 
demonstrated that fatty acid synthase (FAS) was upregulated in HBV-infected cells and the 
reduction of FAS by siRNA would suppress viral replication [27]. Recently, the relationship 
between fatty acid translocase CD36 and HBV has aroused our concern. 
CD36 has been reported to facilitate Hepatitis C virus (HCV) entry in favor of viral 
replication, and blocking CD36 inhibited HCV replication [28]. Several studies have suggested 
that CD36 contributed to virion release in human immunodeficiency virus (HIV)-infected 
macrophages, and CD36 silenced or inhibited by soluble anti-CD36 antibodies showed 
decreasing quantities of HIV virions released [29]. Our previous study demonstrated that CD36 
overexpression enhanced HBV replication in HepG2.215 cells [18]. Here, we found the same 
results in another HBV expression cell line, HepAD38 cells, which are derived from HepG2 
and can replicate HBV under the control of the inducible tetracycline promoter. HepAD38 cells 
produce higher levels of viral DNA by approximately 11-fold compared with HepG2.2.15 cells 
[30]. Given these facts, an advantage of using HepAD38 cells is that HBV DNA replicative 
intermediates are easier to detect compared with HepG2.2.15 cells. This will be especially 
important in assessing antiviral effects in different cell lines to acquire relatively stable data, so 
the two cell lines were assessed in this study. We examined the effect of the depletion of CD36 
on HBV replication and found that the suppression of CD36 possessed antiviral properties in 
both cell lines. These results suggest that the protein levels of CD36 are implicated in HBV 
replication in vitro. 
HBV transgenic mice have been widely used in the functional studies of HBV replication 
and anti-HBV drugs [31,32]. However, the production of transgenic mice is very ambitious and 
expensive. Hydrodynamic injection is a rapid, efficient and convenient gene delivery method 
for in vivo transfection that has widely been used to generate acute HBV infection models via 
the hydrodynamic injection of HBV DNA plasmid [33,34]. In the present study, we successfully 
established an acute HBV infection mouse model via hydrodynamic injection and found that 
CD36 knockout mice had lower levels of HBV replication than wild type mice. The data 
corresponded with the cell experiments, strongly suggesting that CD36 plays an important role 
in regulating HBV replication. 
With the development of transcriptome sequencing technology and bioinformatics, the 
RNA sequencing approach based on next-generation sequencing technology has been 
developed as a powerful tool for transcriptome analysis [35]. To understand the underlying 
molecular basis linking CD36 and HBV replication, we performed RNA sequencing of the 
mRNA from CD36 overexpression and the vector control HepG2.2.15 cells to analyze the 
differential transcriptomic profiles. Our results identified 141 differentially expressed genes in 
response to CD36 overexpression [18]. Unfortunately, the expression of cellular transcription 
factors related to HBV replication was not significantly different between the two groups. Then, 
we focused on some of the differentially expressed genes involved in ion channels and 
homeostasis. Our data suggested that CD36 overexpression affected ion homeostasis, especially 
calcium ion homeostasis, which plays an important role in HBV replication and assembly. 
 Calcium homeostasis is essential for maintaining normal cell function and small as the 
changes in cytosolic calcium levels might be affect the cellular processes [36]. Many viruses 
could regulate intracellular calcium signals by encoding virus proteins to stimulate the viral 
replication of HIV, adenovirus, and Rubella virus [37,38]. For HBV, various studies have 
suggested that HBV x protein (HBx) elevated the basal cytosolic calcium level, which was 
associated with HBV replication in HepG2 cells and cultured primary rat hepatocytes [39,40]. 
The HBx-deficient sample significantly decreased HBV replication and could be rescued by 
simply increasing cytosolic calcium levels [19]. Although the viral-mediated regulation of Ca2+ 
levels has been associated with replicating HBV, host mechanisms that affect Ca2+ signaling to 
regulate viral replication remain unknown. In this study, we found that CD36 expression could 
alter the cytosolic basal calcium levels, with a corresponding alternation of HBV replication in 
both HepG2.2.15 and HepAD38 cells. The calcium chelator BAPTA-AM could override the 
greater HBV replication increased by CD36 overexpression, and the calcium activator 
thapsigargin could improve the lower HBV replication reduced by CD36 knockdown. CD36 is 
just one of the calcium regulators, but CD36 knockdown could decrease the calcium 
concentrations by 29% and 18% in the HepG2.2.15 cells and HepAD38 cells respectively, with 
a corresponding decrease of 70% and 56% in HBV replication in the two cells. Similarly，
Bouchard,et al [19,41] found that one of the function of HBx was to regulate the cytosolic 
calcium, and the calcium levels was decreased by about 25% when HBx was deleted, 
consequently, HBV DNA replication was reduced by 95%. These data suggest that HBV  
leads to endoplasmic reticulum Ca2+ depletion and is followed by the triggering of 
calcium influx into cells to bring about a large increase in cytosolic calcium via SOC channels 
[24,43]. Several studies have suggested that HBx stimulates high levels of viral replication by 
stimulating polymerase activity via the activation of Src kinase and that blocking Src kinase 
could impair viral replication [44]. In this study, we found that high expression levels of CD36 
improved the levels of Src kinase phosphorylation and the production of IP3. SU6656 as a 
commonly used inhibitor for Src replication is very sensitive to the changes in intracellular 
calcium levels. 
In non-excitable cells, such as hepatocytes, increases in cytosolic calcium mainly 
originate from two sources: Ca2+ release from the endoplasmic reticulum Ca2+ stores by the 
activation of IP3 receptors and Ca2+ influx from outside the cell by opening store-operated 
Ca2+ (SOC) channels [42]. Multiple studies have revealed that linoleic acid or palmitate is 
implicated in the phosphorylation of Src kinase by binding to CD36. Consequently, this 
phosphorylation induces the production of IP3, which kinase, could inhibit phosphorylation 
of Src kinase and the following calcium signaling pathways [45]. The Src kinase inhibitor 
SU6656 reduced IP3 secretion and cytosolic calcium levels, with a corresponding decrease 
of HBV replication, suggesting that CD36 regulated HBV replication via the Src kinase 
phosphorylation pathway.  
5. Conclusions 
In general, we have characterized new aspects of fatty acid translocase CD36 biology in 
HBV replication by showing that CD36 overexpression and knockdown are positive and 
negative regulators of HBV replication via cytosolic calcium and the Src kinase pathway, 
respectively. Given the relationship between CD36 and HBV replication, we hypothesize that 
for those HBV-infected patients with a higher expression level of CD36, such as NAFLD and 
MS patients, targeting CD36 may serve as an adjunctive therapeutic means for conventional 
anti-viral drugs. For now, it is still unclear whether CD36 is involved in other steps of the HBV 
life cycle, including virus entry and secretion. Further experiments will be needed to reveal the 
contribution of CD36 to the HBV life cycle. 
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Fig. 1. Overexpression of CD36 promoted HBV replication. (A) Western blotting and 
quantitative analysis of CD36 protein in HepG2.2.15 and HepAD38 cells transfected with 
human CD36 overexpression lentivirus (CD36OE) or vector (n=3) (*** p< 0.001). Actin was 
used as a loading control. (B) Core particles associated with HBV DNA were extracted from 
CD36OE and vector cells after transfection for 4 days and were identified by southern blot. M, 
marker; rcDNA: intracellular HBV relax circle; ssDNA: single-stranded DNA. (C) HBV DNA 
levels were also determined by real-time PCR (n=4). The secretion levels of HBeAg and 
HBsAg in culture medium of CD36OE and vector cells in HepG2.2.15 and HepAD38 cells 
were collected and measured using ELISA. O.D. values were expressed as a percentage relative 
to the vector (n=3) (*P<0.05, **P<0.01). 
Fig. 2. Gene silencing of CD36 inhibited HBV replication. (A) Western blotting and 
quantitative analysis of the CD36 protein in HepG2.2.15 and HepAD38 cells transfected with 
lentiviruses expressing shRNA-targeting CD36 (shCD36) or shRNA-scramble control (shCont) 
(n=3) (*** p<0.001). Actin was used as a loading control. (B) Core particles associated with 
HBV DNA were extracted from shCD36 and shCont cells after transfection for 4 days and were 
identified by southern blot. M, marker; rcDNA: intracellular HBV relax circle; ssDNA: single-
stranded DNA. (C) HBV DNA levels were also determined by real-time PCR (n=4). The 
secretion levels of HBeAg and HBsAg in culture medium of shCD36 and shCont in HepG2.2.15 
and HepAD38 cells were collected and measured using ELISA. O.D. values were expressed as 
a percentage relative to the shCont (n=5). (*P<0.05, **P<0.01 and*** p<0.001). (D) The levels 
of HBs Ag and HBe Ag in serum of HBV-infected WT and CD36KO mice by 
chemiluminescence immunoassay (n=3). HBV DNA levels in the serum and liver were detected 
by real-time PCR (n=4) (*P<0.05, **P<0.01). HBV core protein expression in the liver of HBV-
infected WT and CD36KO mice was visualized by immunohistochemistry using anti-HBcAg; 
arrows indicate HBcAg. 
Fig. 3. Effects of CD36 expression on cytosolic calcium levels. (A) Differentially expressed 
genes from RNA sequencing analysis were involved in ion homeostasis in HepG2.2.15-
CD36OE and HepG2.2.15-vector cells. (B) Overexpression of CD36 in HepG2.2.15 and 
HepAD38 cells increases cytosolic Ca2+. HepG2.2.15-CD36OE, HepAD38-CD36OE and 
vector cells were loaded with the fluorescent Ca2+ indicator Fluo-4/AM after culture for 48 h 
and measured using flow cytometry. Ca2+ concentrations are expressed as relative fluorescence 
(n=3) (*p<0.05, **P<0.01). (C) Knockdown of CD36 in HepG2.2.15 and HepAD38 cells 
decreases cytosolic Ca2+. HepG2.2.15 and HepAD38 cells were transfected with CD36-
shRNA-lentivirus (shCD36) and scramble control-lentivirus (shCont), treated with 4 μM Fluo-
4/AM after 48 h posttransfection, and measured using flow cytometry. Ca2+ concentrations are 
expressed as relative fluorescence (n=3) (** p < 0.01). 
Fig. 4. CD36 regulation of HBV replication is associated with cytosolic calcium signals. (A) 
Calcium chelator (BAPTA-AM) reduces HBV replication in CD36OE of HepG2.2.15 and 
HepAD38 cells. BAPTA-AM or vehicle controls (DMSO) were added to the CD36OE of 
HepG2.2.15 and HepAD38 cells for 96 h, and HBV DNA were extracted and detected by Real-
time PCR (n=4). Cytosolic Ca2+ was measured after treatment for 48 h using flow cytometry 
(n=3). (B) Calcium activator (thapsigargin) rescued HBV replication in CD36 knockdown 
HepG2.2.15 and HepAD38 cells. Thapsigargin (TG) or vehicle controls (DMSO) were added 
to the CD36 knockdown HepG2.2.15 and HepAD38 cells for 96 h, and HBV DNA were 
extracted and detected by real-time PCR (n=4). Cytosolic Ca2+ was measured after being treated 
for 48 h using flow cytometry (n=3). (**P<0.01 and*** p<0.001). 
Fig. 5. CD36 overexpression activated Src kinase, and Src inhibitors override the higher 
HBV replication induced by CD36 overexpression. (A) CD36 overexpression activated Src 
kinase in HepG2.2.15 and HepAD38 cells. The cell protein was collected from CD36-
overexpressing HepG2.2.15 and HepAD38 cells after culture for 72 h. Total Src and the 
phosphorylation levels were detected using western blotting (n=3) (**P<0.01 and*** p<0.001). 
(B) IP3 levels measured by ELISA in CD36OE and vector control of HepG2.2.15 and 
HepAD38 cells (n=3) (*P < 0.05). (C) Src kinase inhibitor (SU6656) decreases cytosolic Ca2+ 
in CD36OE of HepG2.2.15 and HepAD38 cells. SU6656 or vehicle controls (DMSO) were 
added to the CD36OE of HepG2.2.15 and HepAD38 cells for 24h, Cytosolic Ca2+ was 
measured after treatment using flow cytometry (n=3) (*** p<0.001). (D) Src kinase inhibitor 
(SU6656) overrides the higher HBV replication induced by CD36 overexpression. SU6656 or 
vehicle controls (DMSO) were added to the CD36 overexpression of HepG2.2.15 and 
HepAD38 cells for 96 h. HBV DNA were extracted and detected by real-time PCR (n=4). 
(**P<0.01 and*** p<0.001). 
